Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: Breast cancer

4MO - Prognostic implication of 21-gene expression assay in luminal B type hormone receptor-positive breast cancer patients younger than 40 years


03 Dec 2022


Mini Oral session: Breast cancer


Tumour Site

Breast Cancer


Jaewon Hyung


Annals of Oncology (2022) 33 (suppl_9): S1431-S1435. 10.1016/annonc/annonc1118


J. Hyung1, S. Lee2, J. Kim2, H.J. Kim2, B. Ko2, B. Son2, J. Lee2, H.J. Lee3, G. Gong3, H. Lee1, H. Jeong1, J. Jeong1, J.E. Kim1, J. Ahn1, K.H. Jung1, S. Kim1

Author affiliations

  • 1 Oncology, Asan Medical Center, 138-931 - Seoul/KR
  • 2 Surgery, Asan Medical Center, 138-736 - Seoul/KR
  • 3 Pathology, Asan Medical Center, 138-931 - Seoul/KR


Login to access the resources on OncologyPRO.

Abstract 4MO


Recurrence score (RS) based on 21-gene expression assay is widely used to evaluate prognosis and potential benefits of adjuvant chemotherapy (AC) for hormone-receptor positive (HR+) breast cancer (BC) patients (pts). In this study, we investigated clinical significance of RS in premenopausal HR+ BC pts.


HR+ BC pts with age < 50 years at diagnosis who had at least 3 years of follow-up duration from surgery and had 21-gene expression assay in Asan Medical Center, Seoul, Korea, between June 2005 to July 2018 were included. Recurrence-free survival (RFS) by STEEP version 2.0 was compared according to the RS and other clinicopathologic variables.


Among total 567 pts included in this analysis, 117 pts (20.6%) had age < 40 years and 238 pts (42.0%) had luminal B type BC (LB) by 4-IHC, 85 pts (15.0%) had RS > 25, 301 pts (53.8%) had high clinical risk BC as defined by tumor size, lymph node and histologic grade and 92 pts (16.2%) had AC. On univariate analysis, pts with RS > 25 showed poor RFS (log-rank, p = 0.007). Also, pts with age < 40 years (log-rank, p = 0.008), high clinical risk (log-rank, p = 0.030) and LB (log-rank, p = 0.002) had poor RFS. On multivariate analysis, age < 40 years and LB were associated with significantly poor RFS with HR of 2.49 (95% CI 1.16-5.36, p = 0.020) and 2.59 (95% CI 1.11-6.04, p = 0.028), respectively while RS > 25 was not associated with RFS. When compared according to age group (< 40 years vs. 40 years) and luminal types (luminal A (LA) vs. LB), pts with age < 40 years and LB showed significantly poor RFS (HR 4.52, [95% CI 2.08-9.84], p < 0.001) compared to pts with age 40 years or LA. Pts with < 40 years with LB had higher proportion of pts who received AC (35.0% vs. 14.0%, p < 0.001) compared to pts with age 40 years or LA. While RS > 25 was associated with poor RFS among pts with age 40 years or LA (HR 3.20, [95% CI 1.20-8.53], p = 0.020), RS > 25 was not associated with RFS in pts with age < 40 years and LB (HR 1.31, [95% CI 0.34-5.10], p = 0.699).


The RS alone was not prognostic among premenopausal HR+ BC pts especially with age < 40 years and LB, which showed significantly poor RFS compared to pts with age 40 years or LA despite of higher proportion of pts who received AC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.